Eli Lilly's Foundayo weight-loss pill approved in UK, first in Europe
The daily GLP-1 tablet becomes the first European approval for Eli Lilly's oral weight-loss treatment, competing with Novo Nordisk's Wegovy.
Conversation activity · last 38 hours peak 8/hr
Summary, timeline and people extracted by Claude from 16 items across 4 sources · 8h ago. Quotes are verbatim.
Eli Lilly's Foundayo, a daily GLP-1 weight-loss pill, received UK regulatory approval on 2026-08-10, making the UK the first European country to greenlight the drug. The pill can be prescribed privately immediately and Eli Lilly plans to seek NHS recommendations for weight-loss treatment, though it is already approved for type 2 diabetes use on the NHS. The approval marks the company's first Foundayo launch outside the US and signals competitive expansion against Novo Nordisk's Wegovy pill in the European market.
- Eli Lilly's Foundayo received MHRA approval on 2026-08-10, making the UK the first European country to approve the GLP-1 weight-loss pill.
- Unlike Wegovy pill, Foundayo can be taken at any time of day rather than on an empty stomach, and is expected to be cheaper than existing treatments.
- The pill is immediately available for private prescription and on NHS for type 2 diabetes; Eli Lilly plans to apply for NHS weight-loss treatment recommendation via NICE.
- Approval marks Eli Lilly's first Foundayo launch outside the US and signals direct competitive expansion against Novo Nordisk's Wegovy in the European weight-loss market.
How it unfolded
-
Financial observers highlighted that Foundayo's UK approval extends Eli Lilly's weight-loss pill competition with Novo Nordisk beyond the US market.
“Eli Lilly's oral GLP-1 weight-loss pill Foundayo has received UK approval, directly challenging Novo Nordisk's Wegovy in the European market.”
polaronfinance.bsky.social · Bluesky ↗ -
CNBC reported that Foundayo's UK approval represents Eli Lilly's first weight-loss pill launch outside the US, directly challenging Novo Nordisk's Wegovy in the European market.
-
Dr Simon Cork from Anglia Ruskin University noted Foundayo offered significant weight-loss benefits, likely cheaper than alternatives, and unlike Wegovy pill could be taken any time of day rather than on an empty stomach.
“The arrival of another effective oral option is a positive development and should help more people access treatment that best suits their needs and preferences.”
Dr Simon Cork · Mastodon ↗ -
Eli Lilly announced it could immediately use Foundayo on the NHS for type 2 diabetes but would apply to NICE for NHS recommendation as a weight-loss treatment.
-
Event MHRA approves Foundayo
The UK Medicines and Healthcare products Regulatory Agency approved Foundayo (orforglipron), Eli Lilly's daily weight-loss pill, making the UK the first European country to do so.
- 10 weeks quiet
-
The MHRA approved Wegovy pill, a similar GLP-1 weight-loss medication, in June 2026.
What people are saying verbatim
“A daily weight-loss pill made by the drug firm behind the Mounjaro jab has been approved for use in the UK - the first country in Europe to do so.”
BBC News, News outlet · BBC ↗ · Aug 9
“The arrival of another effective oral option is a positive development and should help more people access treatment that best suits their needs and preferences.”
Dr Simon Cork, Academic expert, Anglia Ruskin University · BBC ↗ · Aug 9
“Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.”
CNBC, News outlet · CNBC ↗ · Aug 10
“Eli Lilly's oral GLP-1 weight-loss pill Foundayo has received UK approval, directly challenging Novo Nordisk's Wegovy in the European market.”
polaronfinance.bsky.social, Financial observer · Bluesky ↗ · Aug 10
“Trials found that patients who had used weight loss jabs and then been given the tablet, also called orforglipron, every day for a year avoided regaining much of the weight they had lost.”
BBC News, News outlet · BBC ↗ · Aug 9